01
Clinical
Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers' Precancer Lesions with Microsatellite Instability.
Molecular characterization of precancerous lesions in Lynch syndrome carriers confirms that Nous-209 target mutations occur early in adenoma progression, supporting the vaccine's preventive potential. The study found that Nous-209 mutation counts correlate strongly with microsatellite instability status, with dMMR/MSI-H lesions harboring the highest burden, validating the target population for this NCI-sponsored Phase Ib/II trial.